Gold prices steady ahead of Fed decision; weekly weakness noted
Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported fourth quarter EPS of $1.67, $0.20 better than the analyst estimate of $1.47. Revenue for the quarter came in at $12.34B versus the consensus estimate of $11.54B.
Guidance
Bristol-Myers Squibb sees FY 2025 EPS of $6.55-$6.85 versus the analyst consensus of $6.92.
Bristol-Myers Squibb sees FY 2025 revenue of $45.50B versus the analyst consensus of $46.27B.
Bristol-Myers Squibb’s stock price closed at $59.71. It is up 10.29% in the last 3 months and up 22.76% in the last 12 months.
Bristol-Myers Squibb saw 6 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb’s stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb’s Financial Health score is "good performance".
Check out Bristol-Myers Squibb’s recent earnings performance, and Bristol-Myers Squibb’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar